| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | P42; CCRK; CDCH; PNQALRE |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CDK20 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDK20抗体的参考文献示例(注：以下内容为模拟示例，实际文献可能需要通过学术数据库检索确认)：
---
1. **文献名称**: *"CDK20 promotes hepatocellular carcinoma progression via Wnt/β-catenin signaling and serves as a therapeutic target"*
**作者**: Jiang, L. et al.
**摘要**: 本研究开发了一种高特异性CDK20抗体，用于检测肝细胞癌(HCC)组织中CDK20的过表达。实验表明，CDK20通过激活Wnt/β-catenin通路促进肿瘤增殖，其抗体可用于预后评估及靶向治疗研究。
2. **文献名称**: *"Immunohistochemical analysis of CDK20 expression in colorectal cancer and its correlation with patient survival"*
**作者**: Smith, R. et al.
**摘要**: 通过商业化CDK20抗体进行免疫组化分析，发现结直肠癌中CDK20表达与肿瘤分期和患者生存率显著相关，提示其作为生物标志物的潜力。
3. **文献名称**: *"CDK20 inhibition suppresses neuroblastoma tumorigenesis through cell cycle arrest"*
**作者**: Tanaka, K. et al.
**摘要**: 利用CDK20特异性抗体阻断其功能，证实CDK20在神经母细胞瘤中通过调控G1/S期转换驱动肿瘤生长，为靶向干预提供依据。
4. **文献名称**: *"Development and validation of a novel CDK20 monoclonal antibody for molecular diagnostics"*
**作者**: Zhang, Y. et al.
**摘要**: 研究报道了一种新型CDK20单克隆抗体的开发与验证，该抗体在Western blot和免疫荧光中表现出高灵敏度和特异性，适用于基础研究与临床检测。
---
如需具体文献，建议通过 **PubMed** 或 **Web of Science** 检索关键词“CDK20 antibody”、“CDK20 immunohistochemistry”等获取最新研究。
CDK20 (Cyclin-Dependent Kinase 20), also known as Cell Cycle-Related Kinase (CCRK), is a serine/threonine kinase involved in cell cycle regulation and transcriptional processes. It interacts with cyclins and regulates the activity of RNA polymerase II, impacting gene expression. CDK20 has gained attention due to its overexpression in cancers like hepatocellular carcinoma (HCC), colorectal cancer, and ovarian cancer, where it promotes tumor progression by activating oncogenic pathways such as Wnt/β-catenin. Its role in modulating immune responses and chemoresistance further highlights its therapeutic relevance.
CDK20 antibodies are critical tools for studying its expression, localization, and function in both normal and diseased tissues. These antibodies, often monoclonal or polyclonal, are designed to target specific epitopes of CDK20 and are validated for techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. They help identify CDK20 as a potential biomarker for cancer diagnosis or prognosis. In therapeutic contexts, CDK20 antibodies may aid in developing targeted inhibitors or antibody-drug conjugates (ADCs). Preclinical studies suggest that blocking CDK20 activity could suppress tumor growth and enhance chemotherapy sensitivity. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Ongoing research aims to refine CDK20-targeting strategies for clinical translation.
×
